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RESEARCH

Development and Delivery of a Quality Improvement
Program to Reduce Antipsychotic Polytherapy
Jessica L. Gören, PharmD; Stuart E. Beck, MD; Barry J. Mills, MD, PhD;
Derri L. Shtasel, MD, MPH; and Robert L. Dufresne, PhD

ABSTRACT
BACKGROUND: Although antipsychotic polytherapy is considered appropriate in limited circumstances (e.g., during a brief “cross-titration” period
when switching medications), its increasing prevalence indicates use
beyond this limited scope. Despite absence of support in the medical
literature and higher costs, antipsychotic polytherapy is common in the
treatment of schizophrenia and related disorders. The highest utilization
of antipsychotic polytherapy occurs on psychiatric inpatient units, and
in 2008, the Joint Commission released the first set of 7 hospital-based
inpatient psychiatric services (HBIPS) core measures, 2 of which assess
antipsychotic polytherapy at time of discharge.
OBJECTIVE: To describe the effect on antipsychotic polytherapy at time of
discharge of a 2-part quality improvement program composed of educational seminars and prescriber-specific feedback provided to 11 psychiatrists in 4 acute inpatient psychiatric units in 2 hospitals.
METHODS: In a regional academic health care system, we determined
the prevalence of antipsychotic monotherapy and polytherapy at time of
discharge for all patients discharged on standing antipsychotic medications during 3 periods: (a) a 3-month baseline period (August 2006 through
October 2006); (b) in July 2007, after delivery of 4 educational luncheon
seminars to 11 psychiatrists from November 2006 through June 2007; and
(c) in June 2008, following the provision of monthly prescriber-specific
audit feedback from August 2007 through June 2008. To prepare nurses for
the change and address possible safety concerns, an educational module
was delivered to the psychiatric nursing staff at “best practice” day lectures held in the first quarter of 2007. General themes in the educational
presentations included literature-based reviews of (a) safety and efficacy
of antipsychotic polytherapy, (b) medical risks of antipsychotic medications, (c) specific versus nonspecific effects of these medications, and (d)
effectiveness of first- versus second-generation antipsychotic medications.
The prescriber-specific audit feedback was provided in paper form and
masked the identity of the other prescribers. The chief of service reviewed
audit feedback individually with each psychiatrist on a quarterly basis. The
primary outcome measure was the percentage of patients prescribed 2 or
more antipsychotics at discharge. A secondary outcome measure was the
percentage of patients prescribed 3 or more antipsychotics at discharge.
Differences in the primary outcome measure, comparing (a) July 2007
with the baseline period and (b) June 2008 with July 2007, were analyzed
using Fisher’s Exact tests. The Cochran-Armitage test for trend was used
to assess the relationship between the primary outcome measure and the
extent of the intervention, measured as the 3 time periods. For the secondary outcome measure, the Goodman-Kruskal gamma test for ordered
categorical data was calculated to examine the association between the
the proportion of patients receiving 1, 2, or 3 or more antipsychotics at discharge and the 3 time periods.
RESULTS: The percentage of patients prescribed 2 or more antipsychotics
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at discharge declined from 33.9% at baseline (132 of 389 patients), to
21.8% after delivery of the educational modules (44 of 202 patients,
P = 0.002), and to 12.2% after audit feedback (18 of 147 patients, P = 0.023;
Cochran-Armitage test for trend P < 0.001). When antipsychotic use was
classified as 1, 2, or 3 or more antipsychotic medications, more extensive
intervention was associated with decreased combination use (GoodmanKruskal gamma = 0.39, P < 0.001). In the baseline period, 5.9% of patients
were prescribed 3 or more antipsychotics at discharge. Following completion of the educational and audit components, respectively, the proportion
of patients prescribed 3 or more antipsychotics declined to 2.5% and then
to 0.0%.
CONCLUSION: Educational modules presented to psychiatrists and nurses
in group settings were associated with a decrease in the rate of prescribing 2 or more antipsychotics at discharge from acute psychiatric inpatient
units. Addition of monthly audit feedback provided to psychiatrists was
associated with further decreases.
J Manag Care Pharm. 2010;16(6):393-401
Copyright © 2010, Academy of Managed Care Pharmacy. All rights reserved.

What is already known about this subject
• Because of high cost and lack of evidence of efficacy or
safety, antipsychotic polytherapy, the prescribing of 2 or more
antipsychotics, is discouraged in treatment guidelines except
under limited circumstances (e.g. cross–titration when switching medications or failure/ineligibility for clozapine treatment).
Nonetheless, antipsychotic polytherapy is highly prevalent in
psychiatric inpatient units, with rates of 30%-40% in studies of
acutely hospitalized patients.
• The Joint Commission’s first set of hospital-based inpatient
psychiatric services (HBIPS) core measures (2008) included (a)
decreasing antipsychotic polytherapy at time of discharge and
(b) documentation of appropriate justification for antipsychotic
polytherapy, with appropriate justification defined as a history of
3 or more failed antipsychotic monotherapy trials, cross-titrating
antipsychotic medications with the ultimate goal of antipsychotic
monotherapy, or clozapine augmentation.
• The results of algorithms for decreasing psychotropic polytherapy
and antipsychotic polytherapy have been mixed. Thompson et
al. (2007) found that the likelihood of receiving polytherapy was
decreased after implementing a system of chart reminders, education, and cognitive behavioral techniques but reported that the
improvements were of limited benefit given the labor-intensive
nature of the intervention.
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What this study adds
• This quality improvement program can serve as a potential model
for other inpatient facilities trying to meet the Joint Commission’s
antipsychotic polytherapy HBIPS core measure.
• At baseline, 5.9% of patients discharged from an acute inpatient
psychiatric stay on antipsychotic medication received discharge
prescriptions for 3 or more antipsychotics. After the provision of
education to psychiatrists and nurses, that rate declined to 2.5%.
The rate further declined to 0.0% following the delivery of feedback from 11 monthly audits to psychiatrists.
• Of 389 patients discharged on antipsychotics at baseline, 132
(33.9%) were prescribed 2 or more antipsychotics. After completion of the educational and audit feedback components of the
program, 12.2% (18 of 147 patients) were prescribed 2 or more
antipsychotics at discharge (P < 0.001).

A

ntipsychotic monotherapy with first- and secondgeneration antipsychotics has demonstrated efficacy
in the treatment of schizophrenia and other psychotic
disorders.1,2 However, 20%-35% of patients fail to respond to or
have incomplete response to antipsychotic monotherapy.1,2 For
such treatment-resistant patients, clozapine is the only treatment proven effective.1-3 However, clozapine has some particularly dangerous side effects and requires regular monitoring of
white blood cell count, limiting its use. As a consequence of
this problem, clinicians and patients struggle to find an effective medication regimen. One particularly prevalent medication regimen is concomitant prescription of 2 or more standing
antipsychotics (antipsychotic polytherapy).
Antipsychotic polytherapy has not been consistently proven
effective or safe for patients with no or partial response to
antipsychotic monotherapy.4-6 In the majority of randomized
controlled efficacy trials, antipsychotic polytherapy did not
significantly differ from monotherapy on primary outcome
measures.7-12 Of the randomized controlled efficacy trials
that found differences between groups on primary outcome
measures, 2 studies reported antipsychotic polytherapy superior,11,12 and 1 reported antipsychotic monotherapy more effective.7 Effects on secondary outcome measures were mixed,
but benefits gained with polytherapy were often, although not
always, small. Results of analyses of side effects with polytherapy are mixed.7,9,11-15 Adherence is decreased with antipsychotic
polytherapy,16 and the additional medication costs associated
with antipsychotic polytherapy do not appear to be offset by
cost savings in other areas of treatment.17
Despite these mixed data, the use of antipsychotic polytherapy is common.18-20 Within the California Medicaid population
in 2004, an estimated 13.7% of outpatients with schizophrenia who were treated with antipsychotics received multiple
second-generation antipsychotics.18 Rates are even higher during psychiatric inpatient stays, with antipsychotic polytherapy
394 Journal of Managed Care Pharmacy
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prescribed in up to 40% of psychiatric inpatients.19-21 However,
no antipsychotic is approved for adjunctive use with other antipsychotic agents, and such practice is discouraged in treatment
guidelines.22-25
Not all antipsychotic polytherapy is unjustified. For example, treatment guidelines suggest that cross-titration of antipsychotics is preferable to abrupt discontinuation of a medication when switching from one drug to another.23-25 In addition,
treatment guidelines suggest antipsychotic polytherapy for
patients who are treatment resistant and have failed or are
ineligible for a clozapine trial.23-25 The guidelines caution that
such use is not evidence-based, should be monitored closely,
and discontinued if ineffective.23-25
One of the most commonly cited justifications for antipsychotic polytherapy is treatment resistance.26,27 However,
data suggest that antipsychotic polytherapy is not being
reserved for treatment-resistant populations. Lee and Walker
(2008) reported that in patients continuously enrolled in the
California Medicaid program for at least 3 months, 3.7% of
new users of second-generation antipsychotics received antipsychotic polytherapy as their initial antipsychotic treatment.28
Schumacher et al. (2003) found that 79 of 85 patients (93%)
on antipsychotic polytherapy did not have an adequate trial of
monotherapy (4-9 weeks of optimal antipsychotic monotherapy
dose).27 Even if we presumed that all patients on antipsychotic
polytherapy were truly treatment resistant, Schumacher et al.
found that 97.6% of patients did not receive a trial of clozapine,
the only antipsychotic proven effective for treatment-resistant
schizophrenia.
High prevalence and lack of evidence about safety and
efficacy have produced concerns about antipsychotic polytherapy.29,30 Heeding these concerns, the Joint Commission
in October 2008 released the first set of hospital-based inpatient psychiatric services (HBIPS) core measures, including 2
measures of antipsychotic polytherapy at discharge (Figure
1).30 Patients discharged without antipsychotic medications
represent a different population than those discharged with
antipsychotic medications and are not included in the antipsychotic polytherapy core measure.
In anticipation of the release of the Joint Commission’s antipsychotic polytherapy core measure, the study authors designed
a quality improvement project to address antipsychotic polytherapy. In alignment with the Joint Commission’s core measure, the study’s primary outcome was use of antipsychotic
polytherapy at discharge. Since the project began during
development of the HBIPS core measure, initial data collection was based on early drafts of the measure, which did not
include a measure of appropriate justification of antipsychotic
polytherapy. Therefore, data on justification of antipsychotic
polytherapy were not collected during the earlier portion of
our intervention. Once the core measure criteria expanded to
include appropriate justification of antipsychotic polytherapy,
we began to collect these data.
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FIGURE 1

The Joint Commission’s Hospital-Based Inpatient Psychiatric
Service Core Measures on Antipsychotic Polypharmacy a

Patients Discharged on Multiple Antipsychotic Medications
Denominator Statement: Psychiatric inpatient discharges
Included Populations:
• Patients with ICD-9-CM Principal or Other Diagnosis Codes for Mental Disorders as defined in Appendix A, Table 10.1 discharged on
one or more routinely scheduled antipsychotic medications (refer to Appendix B, Table 10.0- Antipsychotic Medications)
Excluded Populations:
• Patients who expired
• Patients with an unplanned departure resulting in discharge due to elopement
• Patients with an unplanned departure resulting in discharge due to failing to return from leave
Patients Discharged on Multiple Antipsychotic Medications with Appropriate Justification
Denominator Statement: Psychiatric inpatients discharged on two or more routinely scheduled antipsychotic medications
Included Populations: Not applicable
Excluded Populations:
• Patients who expired
• Patients with an unplanned departure resulting in discharge due to elopement
• Patients with an unplanned departure resulting in discharge due to failing to return from leave
• Patients with a length of stay ≤ 3 days
aThe

Joint Commission. Specification Manual for National Quality Measures-Hospital-Based Inpatient Psychiatric Services Test Set.30
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.

■■ Methods
All data were gathered as part of a quality improvement project.
As such, our local institutional review board deemed publication of research using de-indentified patient and psychiatrist
data exempt from institutional review board approval. To
ensure confidentiality during the project, all data analyses were
conducted and reported for internal use with de-identified
patient data.
Setting
At the time of the quality improvement project, Cambridge
Health Alliance (CHA), a regional academic health care system,
consisted of 3 inpatient hospitals, more than 20 outpatient
clinics, a Medicaid health maintenance organization (HMO),
and the Cambridge Public Health Department. As a safety net
hospital system, CHA serves a racially and ethnically diverse
population. Approximately 50% of CHA patients are uninsured or enrolled in Medicaid or Commonwealth Care, the
state health insurance program.
During implementation of the quality improvement program, CHA had 4 acute inpatient adult psychiatric units
housed within 2 hospitals (2 units at each hospital). Each
adult inpatient psychiatric unit cares for approximately 40
patients daily. One hospital follows an academic model, with
residents, students, and interns involved in patient care. The
other hospital follows a community model without trainee
involvement. There were no prescribing guidelines for the use
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of antipsychotic medications prior to initiation of the quality
improvement program.
Educational Component
Reports of educational efforts to improve physician adherence
with evidence-based medicine within and outside of psychiatry have been mixed.31-34 However, an educational program
was considered by the study authors to be crucial to this quality improvement program for several reasons, including the
need to (a) open a dialogue regarding goals and concerns with
the quality improvement program, (b) address the evidence
base supporting the quality improvement program, (c) obtain
clinician “buy-in” for the program, and (d) allow nurses and
psychiatrists access to the same information regarding the
purpose and methods of the quality improvement program.
A pharmacist who is board certified in psychiatric pharmacy
practice worked as part of the interdisciplinary team to develop
and deliver the education.
Educational modules were developed using a disciplinespecific approach. Specific learning objectives are presented in
Table 1. The primary educational goal was to ensure realistic
expectations of what an antipsychotic could do and in what
time frame. The secondary educational goal was to initiate
discussion of the risks of antipsychotic medications, especially
with antipsychotic polytherapy. Discussions centered on risks
and benefits of antipsychotic monotherapy and polytherapy,
relative risks and benefits of first- and second-generation
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TABLE 1

Educational Learning Objectives

• Describe medical risks of antipsychotic medications
• Identify specific versus nonspecific effects of antipsychotic
medications (e.g., sedation vs. psychosis)
• Compare and contrast effectiveness and safety of first- and secondgeneration antipsychotics
• Describe data regarding the safety and efficacy of antipsychotic
polytherapy

antipsychotics, and use of antipsychotics for acute agitation
versus primary psychosis.
All 11 inpatient psychiatrists met as a group 4 times during
the 9-month intervention period. The initial meetings were
in November and December 2006. The remaining 2 seminars
were conducted quarterly during the first and second quarters
of 2007. The meeting site was varied in order to decrease travel
burden on any one group of psychiatrists. Core information
was presented during lunch by the psychiatric pharmacist,
chief of adult psychiatry, and local psychiatry directors from
each hospital. An interactive seminar format was used to
present information and allow psychiatrists to provide input
and express their concerns about antipsychotic polytherapy
in the clinical setting. To engage psychiatrists in discussion,
the seminars included discussions of recent patients who were
particularly complex and challenging.
Nursing staff were included for 2 reasons: (a) to prepare
nursing staff for possible changes in prescribing practices, and
(b) psychiatrists’ prescribing can be influenced by nursing
input, specifically fears about violence on the unit. Given the
goal of preparing nursing staff for possible prescribing changes,
similar educational content was provided to nurses and psychiatrists. Education for nursing staff was conducted during
2007 Q1 through a series of lectures delivered by the psychiatric pharmacist during mandatory nursing “best practice” days.
The format was a 45-minute lecture with a 15-minute question
and answer period. A single lecture was delivered 7 times to
allow maximal nursing participation. Supplemental written
materials were provided. The 10% of psychiatric nurses unable
to attend the lecture due to vacation or sick time received a
printed copy of the lecture and contact information for the
psychiatric pharmacist.
Audit Feedback
Because of the extensive literature on audit feedback as a
method of quality improvement,31 the educational component
was combined with prescribing feedback to improve the likelihood of success. Psychiatrists were provided with monthly
“dashboard” (visual presentation of prescribing data) reports
of their antipsychotic prescribing from August 2007 to June
2008 (Figure 2). They were also provided with de-identified
396 Journal of Managed Care Pharmacy
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peer data for comparison. Data presented in the monthly
dashboard included the number of patients treated, number
of patients treated with antipsychotics, number of patients
treated with monotherapy or polytherapy, patient diagnoses,
and specific antipsychotic combinations used. Psychiatrists
met individually with the chief of service quarterly to review
their antipsychotic prescribing dashboard, discuss concerns,
and offer suggestions for improvements to the antipsychotic
polytherapy project.
Outcome Measures
In alignment with the Joint Commission HBIPS-5 core measure, the primary outcome measure was the number of patients
discharged on 2 or more standing antipsychotic medications
divided by the number of patients discharged on at least 1 antipsychotic.30 Given the potential for increased risks and paucity
of data on use of 3 or more antipsychotics, we believed this
practice could never be justifiable. Therefore, the secondary
outcome measure was prescription of 3 or more standing antipsychotics at discharge. Information on patients discharged
on no antipsychotic was not reviewed because such patients
represent a different population with disorders not responsive
to antipsychotic treatment.
Sample and Data Collection Process
All patients on regularly scheduled antipsychotic medication
for any indication at time of discharge from the 4 acute adult
inpatient units were included. Baseline data were collected
prior to any discussion of antipsychotic polytherapy usage
(August through October 2006). Data following the educational component and the monthly audit component were collected in July 2007 and June 2008, respectively. Appropriate
justification data were collected from November 2007 until the
conclusion of the program in June 2008. Collection of these
data coincided with inclusion of appropriate justification of
antipsychotic polytherapy criteria into drafts of the HBIPS core
measure.
Data were collected from the Meditech Health Care
Information System, the electronic database used in CHA’s
hospital system. Data collected included number of patients
treated, standing antipsychotic medications at the time of discharge, and diagnoses. All cases of antipsychotic polytherapy
were confirmed by a chart review conducted by the chief
of adult psychiatry or chief of psychiatric quality improvement. Justification of antipsychotic polytherapy was confirmed
through chart review by the chief of adult psychiatry.
Data Analysis
A comparison of the use of antipsychotic polytherapy in the
2 hospital settings prior to education was performed using a
Pearson’s chi-square test of independence. As there were no
significant differences between usage in these settings, data
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FIGURE 2
Prescriber X

Overall
discharge
medication

Patients
discharged
on 1 or 2
antipsychotics

Patient Category

Sample Audit Feedback: Antipsychotic Prescribing “Dashboard” a
# Discharges
# Patients on
antipsychotics
% Patients on
antipsychotics
Patient Category
Patients with 1
antipsychotic
Patients with 2
antipsychotics
Patients with 3
antipsychotics
Patients with 4-5
antipsychotics
Total
Drug

ARIP
CLOZ
CPZ
HPD
HPD-D
OZPA
PER
QTP
RPR
RPR-C
ZIP
FLU
FLU-D
Rationale

Adjust

ARIP
1

7/07

8/07

9/07

10/07

11/07

12/07

1/08

2/08

3/08

4/08

5/08

6/08

51

48

27

42

20

55

43

40

18

35

29

67

7/07
22

8/07
13

9/07
7

10/07
11

11/07
8

12/07
11

1/08
10

2/08
10

3/08
2

4/08
7

5/08
6

6/08
8

2

3

14

12

10

10

2

7

6

8

PER

QTP

RPR

RPR-C

ZIP

FLU

FLU-D

43
22

27
13

33
9

22

13

9

CLOZ

CPZ

HPD

33
14

40
8

22
12

23
10

25
10

11
2

20
7

21
6

12
8

1

8

HPD-D OZPA

1

1

No

Anx

Yes
Failed
Mono

BPD

MDD

2

Yes
Cross
Taper

Other Mood
w/Psychosis

Psychosis

SA

Yes
Cross
Taper

Eat

Cog

Total %

Notes

Patients with 1
1
1
2
2
1
88%
Percentages by
antipsychotic
diagnosis sum to
more than 100%
Patients with 2
1
12%
because patients
antipsychotics
can have more
Patients with 3
than 1 diagnosis.
antipsychotics
Patients with 4-5
antipsychotics
Total %
13%
13%
25%
38%
13%
a Numbers shown in the “dashboard” are hypothetical and presented for purposes of illustration only.
Adjust = adjustment disorder; anx = anxiety disorder; ARIP = aripiprazole; BPD = bipolar disorder; CLOZ = clozapine; cog = cognitive disorder; CPZ = chlorpromazine;
eat = eating disorder; FLU (D) = fluphenazine (decanoate); HPD-D = haloperidol (decanoate); MDD = major depressive disorder; Mono = monotherapy; OZPA = olanzapine;
PER = perphenazine; QTP = quetiapine; RPR (C) = risperidone (consta); SA = substance abuse; ZIP = ziprasidone.
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TABLE 2

Antipsychotic Use at Psychiatric
Hospital Discharge

Patients on 1
Patients on 2 or More
Date
Antipsychotic
Antipsychotics
P Valuea
c
August through
257 (66.1%)
132 (33.9%)
October 2006
(baseline)b
July 2007b
158 (78.2%)
44 (21.8%)c
0.002
129 (87.8%)
18 (12.2%)c
0.023
June 2008b
a Fisher’s Exact tests comparing July 2007 with August through October 2006 (second row) and June 2008 with July 2007 (third row).
bAugust through October 2006 is baseline prior to education; July 2007 is the
month following education provided to psychiatrists and nurses from November
2006 through June 2007; and June 2008 is after monthly audit and feedback process performed from August 2007 through June 2008.
cCounts (%) of patients with 3 antipsychotic medications in baseline, July 2007,
and June 2008, were 23 (5.9%), 5 (2.5%), and 0, respectively. P value for comparison of baseline and June 2008 was < 0.001 by Fisher’s Exact test.

were combined across settings. Fisher’s Exact tests were performed on the primary outcome measure, receipt of 2 or more
antipsychotics at discharge. These tests compared (a) July 2007
(the month following completion of the education) with August
through October 2006 (the baseline period) and (b) June 2008
(the month following the completion of the monthly providerspecific feedback) with July 2007. A Pearson chi-square test
of independence and a Cochran-Armitage test assessed the
significance and trend of the relationship between the intervention and antipsychotic polytherapy, using a 2 X 3 table of
the antipsychotic polytherapy measure (i.e., 1 vs. 2 or more
antipsychotics at discharge over the 3 time periods—baseline,
then education alone, then education plus monthly feedback).
The strength of the association between the prescription of 1,
2, or 3 antipsychotics and increasing intervention (i.e., the 3
time periods) was assessed using a Goodman-Kruskal gamma
test. Because no cells had less than 5 expected cases, continuity correction was not required for the Pearson chi-square
tests. The a priori P value for statistical significance was 0.05.
All statistical analyses were performed with Systat 12.0 (Systat
Software Inc., Chicago, IL).
■■ Results
There were 389 patients prescribed at least 1 antipsychotic at
discharge during the baseline period. Bipolar disorder was the
most common diagnosis (37.0%) followed by schizophrenia/
schizoaffective disorder/schizophreniform disorder (32.9%),
major depression (28.0%), other mood disorder with psychosis
(2.1%), and other (3.1%). Patients could be diagnosed with
more than 1 primary psychiatric disorder; hence, the total of
reported diagnoses exceeds 100%. During the baseline period,
109 (28.0%) of patients were treated with 2 antipsychotics,
and 23 (5.9%) were treated with 3 antipsychotics at discharge,
for an overall antipsychotic polytherapy rate of 33.9% (Table
398 Journal of Managed Care Pharmacy

JMCP

July/August 2010

2). Patient case mix and average length of stay did not differ
between baseline and active intervention time periods (data
not shown).
The frequency of antipsychotic polytherapy decreased significantly after the educational and audit feedback components
of the intervention (Pearson chi-square = 28.81, df = 2, P < 0.001;
Figure 3). In July 2007, after the educational modules had been
delivered, of 202 patients prescribed antipsychotics at discharge, 44 (21.8%) were prescribed 2 or more antipsychotics.
This rate represented an absolute reduction of 12.1% compared with baseline (Fisher’s Exact test, P = 0.002). Following
the audit intervention, there was a further reduction to an
antipsychotic polytherapy rate of 12.2% (18 of 147 patients),
representing an absolute reduction of 9.6% (Fisher’s Exact
test, P = 0.023). The Cochran-Armitage test for trend showed a
significant (Pearson chi-square = 28.69, df = 1, P < 0.001) linear
decrease in the proportion of patients who were treated with 2
or more antipsychotic drugs over the 3 time periods (i.e., using
the progressive education to audit strategy).
In July 2007, 5 patients (2.5%) had 3 or more antipsychotics
prescribed at discharge; that number declined to 0 in June
2008. Combinations involving clozapine accounted for less
than 1% of antipsychotic polytherapy at all time points.
When antipsychotic usage was classified as the frequency of
patients receiving 1, 2, or 3 or more antipsychotic medications, the incremental intervention (i.e., 3 time periods) was
associated with decreased combination use (Goodman-Kruskal
gamma = 0.39, P < 0.001).
Justification of antipsychotic polytherapy data were collected from November 2007 until conclusion of the quality
improvement project. Rates of appropriate justification ranged
from 21% to 100%.
■■ Discussion
Our findings of decreased antipsychotic polytherapy during
a quality improvement program are consistent with those of
other reports in the literature. Similar to our report, successful
interventions typically include multifaceted approaches.32-34
The present study is the first, to our knowledge, to find an association between the combination of discipline-specific group
education for nursing and psychiatry staff with audit feedback
and reduced rates of antipsychotic polytherapy.
Other reports address interventions to decrease antipsychotic polytherapy with different quality improvement
programs. Mason et al. (1978) first reported more than 30 years
ago on attempts to reduce antipsychotic polytherapy in state
psychiatric hospitals.35 The authors reported that peer review,
small group educational sessions, audit feedback, and written educational materials on basic principles of antipsychotic
prescribing led to a rate of antipsychotic polytherapy of 152 of
802 (19.0%) at follow-up compared with 357 of 1,190 (30.0%)
at baseline.
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FIGURE 3

100%

Antipsychotic Polytherapy Rates
Educational
Seminarsa

Audit Feedback

90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

2006

July 2007

Patients on 1 antipsychotic
a Starting

September 2007

December 2007

March 2008

Patients on 2 antipsychotics

June 2008

Patients on 3 antipsychotics

November 2006.

In another study, Chong et al. (2006) developed and implemented an evidence-based treatment algorithm for patients
accepted into an early psychosis intervention program.36
Introduction of the algorithm was associated with decreased
antipsychotic polytherapy. However, the algorithm was for
“first break” psychosis and may not be applicable to patients
who have been ill for many years.
In the previous research most similar to the present study,
Thompson et al. (2008) reported a decrease in antipsychotic
polytherapy in a randomized controlled trial involving 19 psychiatric units that included a 3-part intervention of academic
detailing, chart-based reminders, and an educational workbook documenting alternatives to polytherapy, including cognitive behavioral techniques.32 Cognitive challenges to polypharmacy prescribing were identified from the rationales used
by clinicians to justify polypharmacy, and alternatives to polypharmacy were reviewed in workbooks provided to nurses and
physicians. Initial rates of polytherapy were 71 of 204 (34.8%)
and 130 of 270 (48.1%) patients on the control and intervention
units, respectively. Upon completion of the interventions, polytherapy was prescribed in 92 of 220 (41.8%) and 104 of 260
(40.0%) patients on the control and intervention units, respectively. However, given the modest gains and labor-intensive
efforts, the authors recommended caution when interpreting
their results. In contrast, the process described in the present
study was less labor intensive. We did not rely on staff commitment of personal time for the educational program, providing
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the modules during normal working shifts. This feature may
have improved the palatability of educational programs to
psychiatric physicians and nursing staff. This difference may
partially account for the present study’s finding of an absolute
22% decrease in rates of antipsychotic polytherapy.
The present study’s authors noted a decrease in the most
egregious form of antipsychotic polytherapy (3 or more antipsychotics) after the introduction of educational programming
only. Therefore, group education may be useful in decreasing
the most egregious form of antipsychotic polytherapy. Study
results, which represent academic and community hospitals,
demonstrate that focused educational group sessions have the
potential for broad application.
Limitations
First, the health care system in which the present study was conducted is a public health safety net hospital system. Additionally,
33% of sample patients were diagnosed with schizophrenia,
schizoaffective disorder, or schizophreniform disorder, and
55% were diagnosed with bipolar disorder or major depression. As such, our population may not necessarily reflect other
patient populations, including those in other facilities or with
a different diagnostic profile. Second, this study reflects only a
limited number of staff psychiatrists (n = 11). It is possible that
other psychiatrists may be more resistant to prescribing change.
However, the study investigators noted improvements in antipsychotic prescribing patterns in all 11 psychiatrists.
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Third, all units involved in the study were within 1 health
care system. This factor may limit the generalizability of our
findings. However, the study did demonstrate that group educational modules can be conducted despite practice sites being
in more than 1 city or town. Although all educational meetings
in the present study were conducted in person, use of teleconferencing could decrease the time commitment of psychiatry
staff or allow inclusion of remote sites.
Fourth, because the psychiatrists who were the subject of
the intervention were aware of the objective of the quality
improvement initiative, they may have changed their prescribing behavior as a result of being observed and not as a direct
result of either the educational or audit feedback interventions.
However, the Hawthorne effect has been viewed as an acceptable and useful aspect of quality improvement initiatives.37
Fifth, we did not measure whether patients in any time
period also had observations in other periods. To the extent
that this problem occurred, it would have violated the assumptions of the statistical tests used, which assume independent
samples. However, persistence of educational effects into the
audit feedback period for both new and repeat cases was an
intended outcome of the program.
■■ Conclusion
Standardized group educational presentations were associated
with decreases in concomitant use of 2 or more antipsychotics
prescribed at discharge from an acute psychiatric inpatient
stay. The addition of audit feedback was associated with an
additional decrease in the concomitant use of 2 or more antipsychotics.
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